This study sought to test the noninferiority of triple antiplatelet therapy (TAT) versus double-dose clopidogrel dual antiplatelet therapy (DDAT) in patients undergoing percutaneous coronary intervention (PCI).Antiplatelet regimen is an integral component of medical therapy after PCI. A 1-week duration of doubling the dose of clopidogrel was shown to improve outcome at 1 month compared with the conventional dose in patients with acute coronary syndrome undergoing PCI. Yet in Asia, the addition of cilostazol is used more commonly than DDAT in high-risk patients.We randomly assigned 3,755 all-comers undergoing PCI to either TAT or DDAT, which was continued for 1 month, to test the noninferiority of TAT versus DDAT. The primary outcome was the cumulative incidence of net clinical outcome at 1 month post-PCI defined as the composite of cardiac death, nonfatal myocardial infarction, stent thrombosis, stroke, and PLATO (Platelet Inhibition and Patient Outcomes) major bleeding.TAT was noninferior to DDAT with respect to the primary outcome, which occurred in 1.2

作者：Kyung Woo, Park；Si-Hyuck, Kang；Jin Joo, Park；Han-Mo, Yang；Hyun-Jae, Kang；Bon-Kwon, Koo；Byoung-Eun, Park；Kwang Soo, Cha；Jay Young, Rhew；Hui-Kyoung, Jeon；Eun Seok, Shin；Ju Hyeon, Oh；Myung-Ho, Jeong；Sanghyun, Kim；Kyung-Kuk, Hwang；Jung-Han, Yoon；Sung Yun, Lee；Tae-Ho, Park；Keon Woong, Moon；Hyuck-Moon, Kwon；In-Ho, Chae；Hyo-Soo, Kim

来源：JACC. Cardiovascular interventions 2013 年 6卷 9期